Company research
CQENS Technologies Inc.
CIK 1479915Updated Jul 17, 2026
Name history
VapAria Corp · through Dec 18, 2019OICco ACQUISITION IV, INC. · through Aug 12, 2014
Filing activity
Latest filing
50 filings on record · 8-K, 10-Q, NT 10-Q, 10-K, NT 10-K, DEF 14C.
Recent filings
Other Events
Items 8.01, 9.01
10-Q filing
NT 10-Q filing
10-Q filing
10-K filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 13,568,110Source | 7,432,268Source | 2,282,630Source | 2,153,235Source |
| Property, Plant and Equipment, NetUSD | — | — | 157,574Source | 177,722Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 1,741,808Source | 1,386,720Source | 1,144,024Source | 973,823Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,914,107Source | 4,596,556Source | 350,565Source | 219,781Source |
| Assets, CurrentUSD | 9,274,467Source | 4,705,693Source | 394,456Source | 402,494Source |
| Operating Lease, Right-of-Use AssetUSD | 193,185Source | 21,979Source | 79,800Source | 126,235Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,918,223Source | 3,129,718Source | 1,336,664Source | 442,824Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 2,758Source | 2,683Source | 2,618Source | 2,607Source |
| Additional Paid in CapitalUSD | 58,965,838Source | 39,068,448Source | 24,799,273Source | 21,261,500Source |
| Retained Earnings (Accumulated Deficit)USD | -47,789,247Source | -34,763,794Source | -23,856,439Source | -19,553,696Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -4,845Source | -40Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | — | 4,302,550Source | 945,966Source | 1,710,411Source |
| Liabilities and EquityUSD | 13,568,110Source | 7,432,268Source | 2,282,630Source | 2,153,235Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,846,803Source | 3,129,718Source | 1,316,188Source | 368,806Source |
| Operating Lease, Liability, CurrentUSD | 121,765Source | 21,979Source | 59,324Source | 52,217Source |
| Accounts Payable, CurrentUSD | 219,300Source | 961,887Source | 104,179Source | 222,539Source |
| Operating Lease, Liability, NoncurrentUSD | 71,420Source | — | 20,476Source | 74,018Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 249,374Source | 279,138Source | 248,438Source | 94,050Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -13,043,195Source | -10,912,576Source | -4,303,550Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,490,085Source | 1,191,980Source | 1,359,284Source | 3,024,027Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 46,944Source | 68,177Source | -118,360Source | 140,413Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -4,269,253Source | -2,372,214Source | -2,583,282Source | -3,353,697Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -2,345,913Source | -362,182Source | -265,181Source | -364,899Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,833,908Source | — | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,939,650Source | 6,980,467Source | 2,979,247Source | 350,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 4,317,551Source | 4,245,991Source | 130,784Source | -3,368,596Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -6,933Source | -80Source | — | — |
| Additional Financial Items | ||||
| AmortizationUSD | 159,009Source | 125,762Source | 102,577Source | 76,392Source |
| DepreciationUSD | 1,511Source | 157,574Source | 20,148Source | 20,083Source |
| General and Administrative ExpenseUSD | 2,367,546Source | 1,194,810Source | 1,705,655Source | 3,055,176Source |
| Net Income (Loss) Attributable to ParentUSD | -13,025,453Source | -10,907,355Source | -4,302,743Source | -6,244,202Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -17,742Source | -5,221Source | -807Source | — |
| Operating ExpensesUSD | 13,310,430Source | 10,928,392Source | 4,293,840Source | 6,242,693Source |
| Operating Lease, ExpenseUSD | 74,247Source | 62,153Source | 55,476Source | 34,020Source |
| Other Nonoperating Income (Expense)USD | 267,235Source | 15,816Source | -9,710Source | -1,509Source |
| Payments to Acquire InvestmentsUSD | — | — | -1,321Source | — |
| Proceeds from Issuance of Common StockUSD | 10,700,000Source | 6,868,000Source | 2,075,000Source | 350,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of RevenueUSD | 25,000Source | — | — | — |
| Operating Income (Loss)USD | -13,310,430Source | -10,928,392Source | -4,293,840Source | -6,242,693Source |
| Other Nonoperating Income (Expense)USD | 267,235Source | 15,816Source | -9,710Source | -1,509Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -17,742Source | -5,221Source | -807Source | — |
| Net Income (Loss) Attributable to ParentUSD | -13,025,453Source | -10,907,355Source | -4,302,743Source | -6,244,202Source |
| Earnings Per Share, BasicUSD per share | -0.48Source | -0.41Source | 0.16Source | -0.24Source |
| Earnings Per Share, DilutedUSD per share | -0.48Source | -0.41Source | 0.16Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 27,339,471Source | 26,434,607Source | 26,112,501Source | 26,037,266Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 27,339,471Source | 26,434,607Source | 26,112,501Source | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 2,367,546Source | 1,194,810Source | 1,705,655Source | 3,055,176Source |
| Operating ExpensesUSD | 13,310,430Source | 10,928,392Source | 4,293,840Source | 6,242,693Source |
| Operating Lease, ExpenseUSD | 74,247Source | 62,153Source | 55,476Source | 34,020Source |
| Research and Development ExpenseUSD | 1,968,489Source | 1,504,416Source | 1,132,806Source | 1,050,230Source |
Filing attachments
ex4-1.htm · 8-K · 2026-09-03
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 AGREEMENT OF AMENDMENT TO THE SERIES A AND SERIES B COMMON STOCK PURCHASE WARRANTS OF CQENS TECHNOLOGIES INC. This amendment to both the Series A and Series B Common Stock Purchase Warrants of CQENS Technologies Inc. (“ Amendment ”) is dated as of September 3, 2026 (the “ Effective Date ”), by and between CQENS Technologies Inc., a Delaware corporation (the “ Company ”) and Xten Capital Group, Inc., a Minnesota corporation (the “ Holder ”). Company an…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-05
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 March 5, 2026 To Our Shareholders, The past eight months have seen CQENS make significant progress toward our goal of expanding our valuable, worldwide Intellectual Property (“IP”) portfolio, securing US FDA authorization to launch a modified risk tobacco product in the US, and making significant progress with respect to listing our shares for trading in the public market. In terms of our Intellectual Property (“IP”), during the recent period, we…
Read attachment ↗ex99-1.htm · 8-K · 2025-07-17
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 This information statement contains “forward-looking statements.” These statements are based on our current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding actions to be taken in the future, You are urged to carefully review and consider any cautionary statements, including but not limited to expectati…
Read attachment ↗